Apollo Endosurgery, Inc. (APEN)
After hours:
| Previous Close | 9.92 |
| Open | 9.93 |
| Bid | 9.92 x 40700 |
| Ask | 9.98 x 27000 |
| Day's Range | 9.92 - 9.94 |
| 52 Week Range | 3.49 - 10.30 |
| Volume | |
| Avg. Volume | 1,437,157 |
| Market Cap | 471.688M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.05 |
| Earnings Date | May 01, 2023 - May 05, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Simply Wall St.
Does This Valuation Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Imply Investors Are Overpaying?
Key Insights Apollo Endosurgery's estimated fair value is US$7.40 based on 2 Stage Free Cash Flow to Equity Apollo...
- ACCESSWIRE
Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity
Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices
- Zacks
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
